A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
Condition: Rhinitis Allergic; Conjunctivitis
MeSH terms: Rhinitis; Rhinitis, Allergic; Conjunctivitis
Intervention: Grass (Phleum pratense) pollen allergen extract; Placebo for SCH 697243
Intervention description: One dissolving tablet sublingually once daily; One dissolving tablet sublingually once daily
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 1501.0
Sex: All
Minimum age: 5 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243)
      versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
      Participants will receive either the sublingual grass tablet or a placebo tablet during the
      study. It is expected that those participants receiving the active sublingual grass tablet
      will have less hayfever symptoms and need less medications to treat hayfever symptoms during
      the grass pollen season.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Must have a clinical history of significant allergic rhinoconjunctivitis to grass
             (with or without asthma)

          -  Must have a positive skin prick test response to Phleum pratense (Timothy grass)

          -  Must be positive for specific immunoglobulin E (IgE) against Phleum pratense (Timothy
             grass)

          -  Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted
             value at

        Screening

        - Safety laboratory tests and vital signs conducted at the Screening Visit must be within
        normal

        limits or clinically acceptable to the investigator/sponsor

        Exclusion Criteria:

          -  Has a clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to
             another allergen during or potentially overlapping the GPS

          -  Has a clinical history of significant symptomatic perennial allergic rhinitis and/or
             asthma due to an allergen to which the participant is regularly exposed

          -  Has received an immunosuppressive treatment within 3 months prior to the Screening
             Visit

          -  Has a clinical history of severe asthma

          -  Has a history of anaphylaxis with cardiorespiratory symptoms

          -  Has a history of self-injectable epinephrine use

          -  Has a history of chronic urticaria and angioedema

          -  Has a clinical history of chronic sinusitis during the 2 years prior to the Screening
             Visit

          -  Has current severe atopic dermatitis

          -  Is breast-feeding, pregnant, or intending to become pregnant

          -  Had previous treatment by immunotherapy with any grass pollen allergen for more than 1
             month within the 5 years prior to the Screening Visit

          -  Ongoing treatment with any specific immunotherapy at the time of the Screening Visit

          -  Has a known history of allergy, hypersensitivity or intolerance to the ingredients of
             the study drug (except for Phleum pratense), rescue medications, or self-injectable
             epinephrine

          -  Has any clinically significant condition or situation, other than the condition being
             studied that, in the opinion of the investigator, would interfere with the study
             evaluations or optimal participation in the study. Specific examples include but are
             not limited to hypertension being treated with beta blockers, coronary artery disease,
             arrhythmia, stroke, ocular conditions requiring topical beta blockers, any condition
             requiring the use of beta blockers

          -  Has used any investigational drugs within 30 days of the Screening Visit

          -  Is participating in any other clinical study

          -  Is a family member of the investigational study staff conducting this study

          -  Is unable to meet medication washout requirements

          -  Is unlikely to be able to complete the trial, for any reason, or likely to travel for
             extended periods of time during the GPS, which in the opinion of the investigator will
             compromise the data

          -  Has a clinically significant abnormal vital sign or laboratory value that would
             preclude participation in the study